{"title": "International expansion of a novel SARS-CoV-2 mutant", "doi": "10.1101/2020.03.15.20035204", "citation_id": "2020.03.15.20035204v1", "date": "2020-03-17", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.15.20035204", "abstract": "<p>Letter to the editor. There is no abstract. The summary was showed: \nSARS-CoV-2 has inevitably mutated during its pandemic spread to cause unpredictable effects on COVID-19 and complicate epidemic control efforts. Here we report that a novel SARS-CoV-2 mutation (ORF3a) appears to be spreading worldwide, which deserves close attention.</p>", "twitter_description": "Letter to the editor. There is no abstract. The summary was showed: SARS-CoV-2 has inevitably mutated during its pandemic spread to cause unpredictable effects on COVID-19 and complicate epidemic control efforts. Here we report that a novel SARS-CoV-2 mutation (ORF3a) appears to be spreading worldwide, which deserves close attention.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis study was funded by Science & Technology Department of Sichuan Province (Grant number: 2020YFS0004) and West China Hospital of Sichuan University (Grant number: HX-2019-nCoV-066).\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe published genome data are abtained from the GISAID EpiFluTM database and NGDC database.\n\n<https://www.gisaid.org/>\n\n<https://bigd.big.ac.cn/ncov>", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20035204v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20035204v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20035204v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/17/2020.03.15.20035204.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.15.20035204v1", "access_rights": "restricted", "authors": ["Minjin Wang", "Mengjiao Li", "Ruotong Ren", "Andreas Brave", "Sylvie van der Werf", "En-Qiang Chen", "Zhiyong Zong", "Weimin Li", "Binwu Ying"]}